Speakers

Professor Paul Kalra Professor of Cardiology, Portsmouth Hospitals NHS Trust, UK
Professor John McMurray Professor of Medical Cardiology, University of Glasgow, UK

Learning objectives

• The main changes in HFrEF therapy in recent years
• The role of SGLT2 inhibitors and MRAs in the management of HFrEF
• Working with patients and healthcare professionals to improve the management of HFrEF
• Management of HFrEF in people with chronic kidney disease
• Management of high-risk HFrEF patients

Learning module instructions

This BJC TV Learning module has a recommended award of 1 CPD credit for completion (1 hour of learning).
Completion requires a score of at least 80%. If less time is spent learning, then you should claim a reduced credit value.
After you have successfully completed the test you will be able to download your certificate.

References

1. McMurray JJV, Docherty KF. Insights into foundational therapies for heart failure with reduced ejection fraction. Clin Cardiol 2022;45 Suppl 1(Suppl 1):S26–S30. https://doi.org/10.1002/clc.23847

2. Shen L, Jhund PS, Docherty KF, et al. Accelerated and personalized therapy for heart failure with reduced ejection fraction. Eur Heart J 2022;43:2573–87. https://doi.org/10.1093/eurheartj/ehac210

3. Zannad F, McMurray JJV, Krum H; EMPHASIS-HF Study Group, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11–21. https://doi.org/10.1056/nejmoa1009492

4. Matsumoto S, Kondo T, Jhund PS, et al. Underutilization of Mineralocorticoid Antagonists in Patients With Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol 2023;82:1080–91. https://doi.org/10.1016/j.jacc.2023.06.021

5. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022;145:e895–e1032. https://doi.org/10.1161/CIR.0000000000001063

6. Heartfailurematters.org (2023). Aldosterone receptor antagonists or mineralocorticoid receptor antagonist (MRAs). Available at: https://www.heartfailurematters.org/what-your-doctor-can-do/aldosterone-receptor-antagonists-or-mineralocorticoid-receptor-antagonist-mras/#:~:text=What%20they%20do,urine%20and%20are%20weak%20diuretics. (accessed October 2023)

7. National Cardiac Audit Programme (2023). National Heart Failure Audit 2023 Summary Report (2021/22 data). Available at: https://www.nicor.org.uk/wp-content/uploads/2023/10/10633-NICOR-Annual-Summary_Reports_NHFA_AC.pdf (accessed October 2023)

8. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599–3726. https://doi.org/10.1093/eurheartj/ehab368